CStone Announces Oral Presentation at ESMO World GI 2023 for Pivotal Phase 3 Clinical Study of Sugemalimab in First-Line Esophageal Squamous Cell Carcinoma
China - CStone Pharmaceuticals , a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today... | June 13, 2023
Source: marketscreener.com